0.01
-0.0088(-52.38%)
Currency In USD
Address
1100 Massachusetts Avenue
Cambridge, MA 02138
United States of America
Phone
617 453 1000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
30
First IPO Date
July 28, 2000
| Name | Title | Pay | Year Born |
| Ms. Adelene Q. Perkins | Chairman & Chief Executive Officer | 701,507 | 1960 |
| Mr. Seth A. Tasker J.D. | Chief Executive Officer, Senior Vice President, Gen. Counsel & Sec. | 0 | 1979 |
| Dr. Lawrence E. Bloch J.D., M.D. | Treasurer | 513,610 | 1966 |
| Dr. Robert Ilaria Jr., M.D. | Chief Medical Officer | 653,797 | 1961 |
| Jayne Kauffman | Senior Executive Coordinator | 0 | N/A |
| Dr. Jeffery L. Kutok M.D., Ph.D. | Chairman of Scientific Advisory Board | 0 | 1967 |
| Ms. Melissa Hackel | Vice President of Fin. | 0 | N/A |
| Dr. Stephane Peluso Ph.D. | Chief Scientific Officer | 0 | 1971 |
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.